TGFB1 and benign prostatic hyperplasia: In conclusion, GV1001 relieves BPH by suppressing proliferation of prostatic epithelial and stromal cells via interaction with AR, thereby reducing the size of the prostate, reducing PSA levels, inhibiting immune cell infiltration, and preventing TGF-β-mediated EMT.